** Dyne Therapeutics' DYN.O shares down 12.6% premarket to $8.32, lowest since mid-Apr, after overnight follow-on priced
** Co, which focuses on neuromuscular diseases, late Mon said sold ~24.2 mln shares at $8.25 for $200 mln gross proceeds
** Offering priced at 13.3% discount to last sale
** It intends to net offering proceeds to fund ongoing clinical development of its product candidates, per the prospectus
** Also late Mon, Waltham, Massachusetts-based firm said it secured up to $275 mln in debt financing from Hercules Capital
** Morgan Stanley, Jefferies, Stifel and Guggenheim are jt bookrunners for the offering
** With ~113.7 mln shares outstanding, DYN has $1.1 bln market cap
** On Jun 17, DYN shares fell 21% to close at $10.86 after co revised timelines for its genetic disorder therapy following meeting with the FDA
** Through Mon, stock has shed ~60% YTD
(Lance Tupper is a Reuters market analyst. The views expressed are his own)
((lance.tupper@tr.com 1-646-279-6380))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.